IQVIA Holdings, Inc. · NYSE:IQV

IQVIA — Investor Presentation (October 2021)

12 slides from IQVIA's investor presentation, October 2021

  1. Slide 1: Low Complexity Non-Interventional Studies (LC-NIS) Southeast Asia Solution

    Low Complexity Non-Interventional Studies (LC-NIS) Southeast Asia Solution An agile and lean way to generate real world evidence Hiren Thakkar ([email protected]) Principal, Real World Solutions, SEA region October 2021 © 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc

  2. Slide 2: IQVIA LC-NIS offers innovative and flexible real world evidence solutions

    IQVIA LC-NIS offers innovative and flexible solutions to generate real world outcome, health economic, and safety and effectiveness evidence Applied Real-World Solutions Prospective/ Enterprise RW Tech RW Data Retrospective PMA, HTA Primary & Site- Solutions & Centers Solutions and Assets/Networks R

  3. Slide 3: Need for cost-efficient real-world evidence generation in Southeast Asia

    In Southeast Asia, there is a need for relevant, comprehensive and cost- efficient real-world evidence generation in the present market How can IQVIA’s LC-NIS help? High demands for real-world evidence Cost-efficient, smart and • Increasing demand for evidence generation from Scientifically sound st

  4. Slide 4: Evidence required across the drug lifecycle

    With LC-NIS, life science companies are able to answer specific research questions and meet evidence-generation demands across the drug life cycle Evidence required across drug lifecycle Development Growth phase Mature phase Head-to-head Today Affordability comparative Past EVIDENCE REQUIRED PM safe

  5. Slide 5: LC-NIS brings together complementary data sources

    IQVIA’s LC-NIS brings together complementary data sources to quickly and efficiently provide comprehensive real-world data IQVIA LC-NIS Approach National Infrastructure Site-based Data Collection EMR Extraction • Quality registries Bespoke data collection Secure pseudonymized extraction • National r

  6. Slide 6: Different LC-NIS approaches suited for budget and timeline needs

    Depending on your objectives, there are different LC-NIS approaches suited for your budget and timeline needs LC-NIS Approaches Other RWI Offerings Prospective Site Retrospective Physician/ Real World Systematic based Observational Chart Review Patient Survey Databases Review Patient level data Expe

  7. Slide 7: Case study: retrospective chart review for safety and effectiveness data

    IQVIA case study: Using a LC-NIS retrospective chart review, relevant safety and effectiveness RW data was collected to identify clinical outcomes Situation Results • Sponsor aimed to collect RW safety and effectiveness of a new ✓ Collected relevant safety and effectiveness RW data Monoclonal Antibo

  8. Slide 8: Case study: retrospective chart review in Hodgkin Lymphoma

    IQVIA case study: Using a LC-NIS retrospective chart review study, clinical outcomes and patterns were identified and published in a journal Situation Results • Lack of robust Classical Hodgkin Lymphoma (CHL) treatment ✓ Obtained applicable study results that covered multiple patterns and clinical o

  9. Slide 9: Case study: prospective observational study in osteoporosis across APAC

    IQVIA case study: Using an LC-NIS prospective observation research study, clinical outcomes for comparative drugs are being investigated Situation Results • Lack of robust data on RW clinical effectiveness, persistence and ✓ Establishing local presence across APAC markets compliance in Asia Pacific

  10. Slide 10: LC-NIS is an agile and fit-for-purpose delivery model

    LC-NIS is designed as an agile and fit-for-purpose delivery model with stakeholders at the center, suited for local adaptation Local Face to Global Fit-for-Purpose Agile Quality Customer Backbone Tools Framework • Project and site management • RWE Scientific/Epidemiology • Smart and user-friendly ED

  11. Slide 11: IQVIA's strong APAC presence and dedicated teams

    IQVIA’s strong APAC presence and dedicated teams bring local capability with global expertise to deliver LC-NIS studies Local center Capacity of excellence Team with experienced staff with > 50 publications > 125 individuals skilled in RWE on the ground great knowledge about RWE, Scientific/Epidemio

  12. Slide 12: For more information, please contact us

    For more information, please contact us or reach out to your local/regional IQVIA representative Hiren Thakkar Principal, RWS, SEA region [email protected]

Iqvia — Investor Presentation (October 2021) on 6ix